TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24683583
Drug: In situ
Approvals — FDA: no, EMA: no, PMDA: no
Description: In situ tissue‐engineered graft containing 54 ± 38 CD34+ cells/mL, rhBMP-2 (1 mg/cm of defect), and crushed cancellous allogeneic bone (Group A)
Study: 24683583
Drug: In situ
Approvals — FDA: no, EMA: no, PMDA: no
Description: In situ tissue‐engineered graft containing 1,012 ± 752 CD34+ cells/mL, rhBMP-2 (1 mg/cm of defect), and crushed cancellous allogeneic bone (Group B)
Study: 20682875
Drug: Albendazole (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (three daily 400-mg doses)
Study: 15923800
Drug: Prochlorperazine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine (15 mg spansules twice daily)
Study: 15923800
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg tablets twice daily)
Study: 15923800
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg tablets twice daily)
Study: 10994404
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg adenosine
Study: 10994404
Drug: 18 mg
Normalized name: niacin 18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg adenosine
Study: 10323120
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia in the anterior mucobuccal fold
Study: 1462581
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg propranolol retard in one dose daily for 10 days
Study: 30374831
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine digluconate and 0.2% sodium hyaluronate treatment
Study: 30374831
Drug: Neutral solution
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral solution (placebo)
Study: 27099245
Drug: Fructose (52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (52 g)
Study: 27099245
Drug: Sucrose (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (65 g)
Study: 27099245
Drug: Sucralose (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralose (0.1 g)
Study: 25263326
Drug: Blueberry treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blueberry treatment (300 g of blueberry) + smoking
Study: 25263326
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (300 mL of water with sugar) + smoking
Study: 22215709
Drug: Purified serum
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified serum IgG from patients with β2 and/or M3 receptor agonistic activity
Study: 22215709
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of IgG from patients
Study: 22215709
Drug: Sequential addition
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential addition of β‐blocker propranolol
Study: 22215709
Drug: Sequential addition
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential addition of NO synthase inhibitor N(G)‐nitro‐L‐arginine methyl ester
Study: 17453366
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise regimen (12-week training including guided aerobic exercise once a week and home exercise sessions twice a week)
Study: 9739036
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral food supplements for 4 weeks in addition to hospital food
Study: 3196076
Drug: metaproterenol sulfate
Normalized name: Metaproterenol Sulfate
DrugBank: Orciprenaline (DB00816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: metaproterenol sulfate in aerosolized saline solution
Study: 10546188
Drug: Artemether (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether (3.6 mg/kg on day 1, 1.6 mg/kg for the next 4 days)
Study: 10546188
Drug: Quinine (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (1.6 mg/kg for the first 4 hours, 8 mg every 8 hours for the next 3 days)
Study: 8912545
Drug: Negative estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative estrogen receptor (ER) detection by immunohistochemistry (IHC)
Study: 6120706
Drug: Gel containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel containing fomocaine and diphenhydramine
Study: 31782408
Drug: Oxycodone (Oxy)
Normalized name: oxycodone hydrochloride Oral Tablet [M-Oxy]
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone (Oxy)
Study: 23446109
Drug: Methylphenidate (20
Normalized name: methylphenidate (20/80 release) 25 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (20 to 40 mg/day)
Study: 21062669
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oral estradiol valerate
Study: 19608684
Drug: Direct sequencing
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct sequencing alone or in combination with denaturing high-performance liquid chromatography
Study: 1676117
Drug: Ribavirin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (15 mg/kg daily by mouth, average daily dose 1000 mg)
Study: 6219690
Drug: 13‐cis‐retinoic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13‐cis‐retinoic acid (0.5 mg/kg b.w.)
Study: 29757354
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily exercises)
Study: 22663901
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for psychosis (CBTp)
Study: 20806117
Drug: Apixaban 10
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 10 mg once daily
Study: 16433247
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (10 nM, 1 M, and 100 M)
Study: 10389797
Drug: Chilled 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chilled 5% albumin (5 mL/kg at 1‐6 degrees C) infused over 5 min
Study: 10389797
Drug: Chilled 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chilled 5% albumin (5 mL/kg at 1‐6 degrees C) infused over 30 min
Study: 21038647
Drug: Tongfu Granule
Normalized name: GINGER 4.5 g in 100 mL TOPICAL LIQUID [Gongfu Head Soup Plant and extract platycypresssolution]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongfu Granule (TFG), 1 bag, three times per day, for 7 days via oral intake or gastric infusion
Study: 21038647
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered in the same manner as TFG
Study: 16112071
Drug: Oral artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral artemether (6 mg/kg) administered once every 2 weeks for 9-11 doses
Study: 16112071
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered once every 2 weeks for 9-11 doses
Study: 7750316
Drug: Diltiazem (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (0.1 mg/kg bolus, continuous infusion at 2 micrograms/kg/min during surgery, and 30 mg nasogastric tube every 8 hours)
Study: 2308471
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.3 mg/kg O.D.
Study: 2308471
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.3 mg/kg B.I.D.
Study: 2308471
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.6 mg/kg O.D.
Study: 22950654
Drug: AZD7687 (5-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7687 (5-60 mg, oral administration)
Study: 12699264
Drug: Postoperative medical
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative medical therapy (progestins with or without estrogens)
Study: 12699264
Drug: Various drugs
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various drugs used before or after surgery
Study: 8869864
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg twice daily (high dose)
Study: 8869864
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg twice daily (low dose)
Study: 6402342
Drug: Sustained-release buccal
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release buccal nitroglycerin (BNTG)
Study: 30818032
Drug: Mindfulness-Based Stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Stress Reduction (MBSR) plus Treatment as Usual (TAU)
Study: 29324303
Drug: Fulvestrant 500
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg (first-line)
Study: 29324303
Drug: Fulvestrant 250
Normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant 250 mg (first-line)
Study: 29324303
Drug: Fulvestrant 500
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg (second-line)
Study: 29324303
Drug: Fulvestrant 250
Normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant 250 mg (second-line)
Study: 27871510
Drug: Atropine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.5 mg IV bolus)
Study: 21471025
Drug: Fentanyl (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1-2 μg/kg/h intravenously)
Study: 21471025
Drug: Tramadol (0.1-0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (0.1-0.2 mg/kg/h intravenously)
Study: 18395326
Drug: Once-daily vardenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily vardenafil 10mg for 12 weeks
Study: 18395326
Drug: Once-daily vardenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily vardenafil 10mg for 24 weeks
Study: 18395326
Drug: Once-daily vardenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily vardenafil 10mg (12 weeks) vs On-demand vardenafil (24 weeks) after washout
Study: 14534517
Drug: Morphine (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (7.5 mg intravenous infusion over 3 hours)
Study: 14534517
Drug: Quinidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (800 mg, placebo-controlled)
Study: 11406740
Drug: Oral enteric‐coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral enteric‐coated pamidronate (300 mg daily)
Study: 11406740
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (3 g daily)
Study: 31724352
Drug: Needle-knife treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-knife treatment, applied 1 time a week for 8 times, targeting specific anatomical points.
Study: 31724352
Drug: Hydroxychloroquine sulfate,
Normalized name: Hydroxychloroquine Sulfate, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine sulfate, 0.2 g each time, 2 times daily for 4 weeks, total of 2 courses.
Study: 27521445
Drug: subunit cancer
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: subunit cancer vaccine (recMAGE‐A3 protein+AS15)
Study: 27521445
Drug: subunit cancer
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: subunit cancer vaccine (recMAGE‐A3 protein+AS15) with intravesical BCG
Study: 23729804
Drug: Retreatment using
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retreatment using other agents
Study: 18989589
Drug: Immediate autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate autologous bone graft combined with secondary dental implant
Study: 19037084
Drug: Rofecoxib 25
Normalized name: rofecoxib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 25 mg QD
Study: 28891445
Drug: Anti-dementia drug
Normalized name: ANTI-DEMENTIA DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-dementia drug treatment
Study: 26758039
Drug: Pulse methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulse methylprednisolone followed by a 25-month course of oral prednisolone (P group, n = 20)
Study: 26758039
Drug: Combined with
Normalized name: Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined with mizoribine (150 mg/day for 24 months, M + P group, n = 20)
Study: 25189430
Drug: Clonidine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.2 mg oral tablet one hour before surgery, plus 0.2 mg·day(‐1) transdermal patch placed one hour before surgery and removed four days after surgery or hospital discharge)
Study: 17679361
Drug: Melatonin, 5
Normalized name: Melatonin, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin, 5 mg daily for 6 weeks
Study: 17679361
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Epigastric Pain Syndrome (before treatment)
Study: 17679361
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Postprandial Disorders Syndrome (before treatment)
Study: 10541775
Drug: Repro-Dose morphine
Normalized name: Vital E- Repro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repro-Dose morphine (RDM) once daily
Study: 10541775
Drug: MST Continuous
Normalized name: morphine sulfate Oral Suspension [MST Continus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MST Continuous (MST) twice daily
Study: 2682347
Drug: fenfluramine treatment
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenfluramine treatment
Study: 27066188
Drug: Probiotic Lactobacillus
Normalized name: Probiotic Lactobacillus Acidophilus Caplets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic Lactobacillus casei (4 × 10(8) CFU) with prebiotic Inulin (400 mg)
Study: 24553574
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ethanol
Study: 24553574
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ethanol
Study: 22682276
Drug: Expected standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expected standard practice in malaria diagnosis and treatment
Study: 21060104
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (starting at 2000 mg/d)
Study: 21060104
Drug: Azathioprine (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (starting at 2 mg/kg/d)
Study: 15743365
Drug: Dexloxiglumide 200
Normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexloxiglumide 200 mg t.i.d. for 7 days
Study: 12038783
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of tinzaparin (175 IU/kg)
Study: 12038783
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of tinzaparin (75 IU/kg)
Study: 12038783
Drug: Tinzaparin (weight-adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin (weight-adjusted dosing)
Study: 2763876
Drug: High dietary
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dietary calcium intake (1752 mg elemental Ca per day)
Study: 2763876
Drug: Low dietary
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dietary calcium intake (391 mg elemental Ca per day)
Study: 2763876
Drug: Calcium infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium infusion (2 mg Ca per kg body weight over 5 minutes)
Study: 2763876
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium load (500 mg as CaCO3)
Study: 2763876
Drug: Calcium supplements
Normalized name: CALCIUM SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplements (1500 mg Ca per day as CaCO3)
Study: 2763876
Drug: Low-Ca diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Ca diet (approximately 400 mg Ca per day)
Study: 7174
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose aerosolized carbuterol
Study: 7174
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose aerosolized isoproterenol
Study: 30323359
Drug: 8IU intranasal
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8IU intranasal oxytocin
Study: 25156269
Drug: Rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10 mg/d, every night for ≥6 months)
Study: 16618008
Drug: Hallucination-focused integrative
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hallucination-focused integrative treatment (HIT)
Study: 16618008
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (RT)
Study: 12202967
Drug: Propranolol (Inderal,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (Inderal, 40 mg)
Study: 10702882
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of cilostazol (50 to 200 mg)
Study: 10702882
Drug: Repeated oral
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated oral administration of cilostazol (100 mg every 12 hours)
Study: 10702882
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of cilostazol (50 to 200 mg) and repeated doses (100 mg every 12 hours)
Study: 8566601
Drug: Ligation plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ligation plus sclerotherapy (1 mL 1.5% tetradecyl injected just above each band)
Study: 1909152
Drug: Intermittent transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent transdermal glyceryl trinitrate (mean dose 18.2 mg over approximately 16 hours)
Study: 1909152
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with 10 mg per 24 hours of transdermal glyceryl trinitrate
Study: 6688154
Drug: Profile group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Profile group (computerized drug profiles)
Study: 31910101
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D 70 μg (2800 IU)/day
Study: 31910101
Drug: Anti-thyroid medication
Normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-thyroid medication (ATD)
Study: 28368269
Drug: Probiotic group
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic group (n=52) received a multicomponent probiotic formulation of Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum and Saccharomyces boulardii once a day at a dose of 1.25×10^9 CFU from the time of initiation of enteral feeds till discharge
Study: 23713294
Drug: Wuhuang Tangkangling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuhuang Tangkangling (decoction daily for 8 weeks)
Study: 23713294
Drug: Pioglitazone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15 mg x d(‐1) orally once a day) combined with insulin subcutaneous injection
Study: 21606263
Drug: Low-dose MDCT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose MDCT and CT enterography with adaptive statistical iterative reconstruction (ASIR)
Study: 21606263
Drug: Low-dose MDCT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose MDCT and CT enterography with ASIR
Study: 21606263
Drug: Standard-dose 64-MDCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose 64-MDCT and CT enterography with filtered back projection (FBP)
Study: 15042546
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of L-AGE and H-AGE groups
Study: 9736563
Drug: Rufloxacin 200
Normalized name: ofloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rufloxacin 200 mg once daily for days 2 to 7
Study: 7817333
Drug: Analgesic treatment
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic treatment consisting of water and sucrose
Study: 25903286
Drug: MVMH supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVMH supplement
Study: 24108248
Drug: 0.5% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ropivacaine or bupivacaine (5 mL or less)
Study: 24108248
Drug: 0.5% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ropivacaine or bupivacaine (10 mL or greater)
Study: 24108248
Drug: Injection volumes
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection volumes of 2.5 and 5 mL
Study: 24108248
Drug: Injection volumes
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection volumes greater than or equal to 10 mL
Study: 24108248
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 0.5% bupivacaine or ropivacaine
Study: 11231996
Drug: Insulin levels
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin levels calculated over 270 min
Study: 9562229
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation (desmopressin nasal spray)
Study: 9562229
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (desmopressin nasal spray)
Study: 961473
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion during fructose infusion
Study: 961473
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of fructose and amino acids